Macrogenics ‘DART[s]’ into IPO Queue and Seeks $60M
By Jennifer Boggs
Friday, September 6, 2013
Macrogenics Inc. joined the roster of biotechs to file for initial public offerings (IPOs) this year, filing an S-1 with aims of raising up to $60 million to support its cancer drug pipeline.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.